Gynaecologic malignancies
Read more
Lenvatinib plus pembrolizumab delays the time to deterioration of quality of life
In advanced pre-treated endometrial cancer, patient-reported outcomes support efficacy benefits of the combination therapy
Don't miss
-
Poster Display session
17 June 2022, 12:15-13:00 -
Keynote lecture
17 June 2022, 14:15-14:45 -
Mini Oral session
18 June 2022, 13:00-14:00
EDITORIAL
Is molecular profiling for gynaecological cancers worth the cost?
In this era of precision medicine, affordable profiling is essential
HIGHLIGHTS
What is the state of play for molecular profiling in gynaecological malignancies?
Two studies investigate the value of molecular profiling in the management of ovarian and endometrial cancers
How to improve cervical cancer screening in low- or middle-income countries?
Data presented at the ESMO Gynaecological Cancers Congress 2022 confirm the vital role of national screening programmes and highlight the importance of local access
Topics
OPINION
Recent advances fuelled by translational research reflect a greater focus on patients’ quality of life
Eric Pujade-Lauraine